retatrutide phase 2 trial ESC 2024: improves lipid and cardiovascular risk profile in II Phase 2 Trial of Retatrutide

This is the first time the GIP/GLP-1 advantage over GLP-1 alone has been proven in a direct comparison, and it is why I treat "tirzepatide beats semaglutide" as a settled question rather than an open debate

YY , GLP-1

And they need to learn how to inject the medications (or need to commit to taking a daily pill)

If this applies to you, start lighter than you think you need to

However, the net outcome of central stimulation leads to more prominent reductions in appetite, blood glucose and body weight in adult females, suggesting that GLP-1 receptor treatments are more effective treatments for diabetes and obesity in females compared to males